Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Arimidex Observational: Reason for and Effect of Change From Tamoxifen (ARREST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00246961
Recruitment Status : Completed
First Posted : November 1, 2005
Last Update Posted : October 12, 2007
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.

Condition or disease
Breast Cancer

Layout table for study information
Study Type : Observational
Enrollment : 200 participants
Time Perspective: Prospective
Official Title: Arimidex: Reason for and Effect of Change From Tamoxifen
Study Start Date : July 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cardiac Arrest





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Postmenopausal
  • Hormone sensitive breast cancer
  • Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago

Exclusion Criteria:

  • Visceral metastases
  • Patients with signs of progression at the moment of changing therapy
  • Patients who have used other endocrine treatments for breast cancer besides tamoxifen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00246961


Locations
Layout table for location information
Netherlands
Research Site
'S-Gravenhage, Netherlands
Research Site
's-Hertogenbosch, Netherlands
Research Site
Alkmaar, Netherlands
Research Site
Antwerpen, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Bergen op Zoom, Netherlands
Research Site
Boxmeer, Netherlands
Research Site
Breda, Netherlands
Research Site
Doetinchem, Netherlands
Research SIte
Dordrecht, Netherlands
Research Site
Ede, Netherlands
Research Site
Eindhoven, Netherlands
Research Site
Enschede, Netherlands
Research Site
Geldrop, Netherlands
Research Site
Groningen, Netherlands
Research Site
Harderwijk, Netherlands
Research Site
Helmond, Netherlands
Research Site
Hoogeveen, Netherlands
Research Site
Hoorn, Netherlands
Research Site
Leiden, Netherlands
Research Site
Oosterhout, Netherlands
Research Site
Purmerend, Netherlands
Research Site
Roermond, Netherlands
Research Site
Roosendaal, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Schiedam, Netherlands
Research Site
Terneuzen, Netherlands
Research Site
Tiel, Netherlands
Research Site
Venray, Netherlands
Research Site
Vlissingen, Netherlands
Research Site
Winterswijk, Netherlands
Research Site
Zoetermeer, Netherlands
Research Site
Zutphen, Netherlands
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: AstraZeneca The Netherlands Medical Director, MD AstraZeneca

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00246961    
Other Study ID Numbers: D5392NL0002
ARREST
First Posted: November 1, 2005    Key Record Dates
Last Update Posted: October 12, 2007
Last Verified: June 2007
Keywords provided by AstraZeneca:
Adjuvant
Additional relevant MeSH terms:
Layout table for MeSH terms
Tamoxifen
Anastrozole
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action